about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

'Deeply com­mit­ted' Jim Wil­son pours more of his life's work in­to Pas­sage Bio — lock­ing in more gene ther­a­py ...

6 years ago
Deals
Cell/Gene Tx

Covid-19 roundup: Mod­er­na adds vac­cine ex­perts as PhI­II tri­al looms; Feng Zhang group snags in­stant OK on ...

6 years ago
Coronavirus

Step­ping on Bio­Mar­in's turf, PTC Ther­a­peu­tics picks up PKU drug for a song

6 years ago
Deals

'It's pure art': Ver­sant, GV re­veal $60M bet that a clear­er look at in­flam­ma­somes can lead to bet­ter drugs

6 years ago
Financing
Startups

Covid-19 roundup: Epi­demi­ol­o­gist cred­it­ed for shap­ing UK pol­i­cy vi­o­lates lock­down mea­sures; Here's Gilead’s glob­al ...

6 years ago
Coronavirus

Two years af­ter U2 dis­ap­point­ment, TG Ther­a­peu­tics wins back in­vestors with PFS win — set­ting the stage for NDA

6 years ago
R&D

A UCSD cen­ter that's been fa­cil­i­tat­ing Covid-19 clin­i­cal re­search gets $55M from NIH to boost trans­la­tion­al work

6 years ago
R&D
Discovery

With the pric­ing ball in Gilead’s court, ICER of­fers some pa­ra­me­ters on how it can be played — an­a­lyst sees at ...

6 years ago
Coronavirus

Covid-19 roundup: Catal­ent signs an­oth­er Covid-19 man­u­fac­tur­ing deal; Eli Lil­ly's an­ti­body part­ner grabs $175M+

6 years ago
Coronavirus

Covid-19 roundup: Am­gen toss­es Ote­zla in­to an­ti-in­flam­ma­to­ry mix; Trump thick­ens plot around US probe in­to virus ...

6 years ago
Coronavirus

What does a post-pan­dem­ic IPO fil­ing look like? Hong Kong biotech ap­pli­ca­tion of­fers clues

6 years ago
Financing
China

As­traZeneca vaults to the front of the Covid-19 vac­cine race, team­ing up to glob­al­ize Ox­ford can­di­date

6 years ago
Deals
Coronavirus

In the heart of Texas, the AveX­is crew gath­ers for an­oth­er go at gene ther­a­py with $30M and a pow­er­house aca­d­e­m­ic ...

6 years ago
Financing
Startups

Covid-19 roundup: J&J part­ners with Catal­ent on 1B dose vac­cine goal; BioN­Tech, Pfiz­er be­gin mR­NA vac­cine tri­al in ...

6 years ago
Coronavirus

Covid-19 roundup: Re­searchers claim tri­al suc­cess for Roche's Actem­ra as Alex­ion jumps in; Pfiz­er gam­bling $500M on ...

6 years ago
Coronavirus

With ex­pan­sive Covid-19 clin­i­cal plan in full gear, Ox­ford team re­ports pos­i­tive an­i­mal da­ta on ade­n­ovirus-based ...

6 years ago
Coronavirus

#AACR20 roundup: Tecen­triq/Xtan­di com­bo fails to show OS ben­e­fit, halt­ing Roche's PD-L1 push in­to prostate can­cer

6 years ago
R&D

#AACR20: Io­vance rev­els in promis­ing lung can­cer da­ta out of Mof­fitt as TIL ther­a­py trig­gers 2 com­plete re­spons­es

6 years ago
R&D

Covid-19 roundup: Sanofi promis­es to bring re­com­bi­nant vac­cine ca­pac­i­ty to 1B+ while scal­ing up mR­NA man­u­fac­tur­ing

6 years ago
Coronavirus

Covid-19 roundup: Har­vard sci­en­tist who in­vest­ed in Mod­er­na ear­ly be­comes a pan­dem­ic bil­lion­aire — and he's giv­ing ...

6 years ago
Coronavirus

First NDA in. Re­gion­al deal done. Now My­ovant has PhI­II da­ta to back up re­l­u­golix's push to an­oth­er block­buster ...

6 years ago
R&D

Covid-19 roundup: Carl June on hav­ing Covid-19 and his plan to treat it; NIH preach­es cau­tion; 2 new vac­cines en­ter ...

6 years ago
Coronavirus

Amid remde­sivir craze Gilead finds time for an­oth­er on­col­o­gy pact — loop­ing in all things NK cells

6 years ago
Deals

Astel­las snaps up mi­to­chon­dria-fo­cused biotech, beefs up drug dis­cov­ery in bud­get deal

6 years ago
Deals
First page Previous page 76777879808182 Next page Last page
A service from the Financial Times